指南与共识骨软组织肉瘤与黑色素瘤

黑色素瘤再治疗与再挑战:共识定义提案

The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions.
指南 / 共识 · Eur J Cancer · 2020-08-26

针对BRAF突变黑色素瘤患者,在BRAF/MEK抑制剂治疗停药或干预后重复治疗可能带来临床获益,该文提出「再治疗」和「再挑战」的共识定义以统一术语。再治疗指辅助治疗结束后复发时重复使用同一治疗类别,再挑战指不可切除或转移性疾病既往治疗有临床获益后进展时重复使用同一治疗类别,该概念也可能适用于免疫检查点抑制剂。

要点

  • 再治疗:辅助治疗结束后复发时重复使用同一治疗类别。
  • 再挑战:不可切除或转移性疾病既往治疗有临床获益后进展时重复使用同一治疗类别。
  • 统一术语有助于推动和协调该领域的进一步研究。

核心结论

  • 该文提出黑色素瘤再治疗与再挑战的共识定义,以统一术语并促进该领域研究。

研究设计与样本

  • 该文为欧洲癌症杂志(Eur J Cancer)发表的共识定义提案,针对BRAF突变黑色素瘤的重复治疗术语提出定义。

主要发现

  • 再治疗定义为辅助治疗结束后复发时重复使用同一治疗类别。
  • 再挑战定义为不可切除或转移性疾病既往治疗有临床获益后进展时重复使用同一治疗类别。
  • 重复BRAF/MEK抑制剂治疗可能带来临床获益,与MAPK通路在黑色素瘤癌变中的作用及BRAF/MEK抑制剂特异性耐药机制有关。
  • 再治疗与再挑战概念也可能适用于黑色素瘤患者的免疫检查点抑制剂治疗。

关键数值与推荐

  • 再治疗适用于完成既往辅助治疗或因毒性提前终止辅助治疗后的不可切除或转移性疾病患者,或辅助治疗后局部区域复发随后接受切除的患者。
  • 再挑战适用于初始缓解后进展并接受替代干预治疗的患者,或对BRAF/MEK抑制剂治疗有缓解后停药的患者。

临床怎么用

  • 临床讨论BRAF突变黑色素瘤重复治疗时应使用统一的再治疗与再挑战定义。
  • 对辅助治疗后复发或不可切除/转移性疾病既往治疗有临床获益后进展的患者,可考虑重复使用同一治疗类别。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with BRAF-mutant melanoma commonly develop resistance to BRAF inhibitor and MEK inhibitor (BRAF/MEKi) treatment, resulting in disease recurrence or progression. Repeated treatment after a break or an intervening therapy may provide clinical benefit. To ensure a common understanding when discussing the treatment of BRAF-mutant melanoma, we propose consensus definitions for retreatment and rechallenge. 'Retreatment' should be defined as 'repeated treatment with the same therapeutic class following relapse after adjuvant treatment has ended.' Retreatment may be an option for patients with unresectable or metastatic disease who have completed prior adjuvant therapy or discontinued adjuvant therapy early due to toxicity or patients with locoregional recurrence after adjuvant treatment who subsequently underwent resection. 'Rechallenge' should be defined as 'repeated treatment with the same therapeutic class following disease progression in patients who had clinical benefit with prior treatment for unresectable or metastatic disease.' Rechallenge may be an option for patients who had disease progression after an initial response and received an alternative intervening treatment or patients with unresectable or metastatic melanoma who had a treatment break after responding to BRAF/MEKi therapy. Clinical benefits may be possible with repeated BRAF/MEKi treatment because of the role of the MAPK pathway in melanoma oncogenesis and resistance mechanisms specific to BRAF/MEKi, which are discussed in this article. The concepts of retreatment and rechallenge may also be relevant for treatment with immune checkpoint inhibitors in patients with melanoma. Use of consistent terminology will help to stimulate and align further research in this area.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Gebhardt C, Ascierto P, Atkinson V, et al. The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions. Eur J Cancer. 2020. PMID: 32861208. doi:10.1016/j.ejca.2020.07.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。